A new biotech incubator, which will be located at CSL’s new Global Headquarters in Melbourne, Australia, is welcoming expressions of interest ahead of its 2024 launch.
Blue Water Vaccines has signed an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.
GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.
A Phase 3 trial for Northwest Biotherapeutics’s DCVax-L vaccine extended survival in patients with gliobastoma for many months, or in some cases, years: according to new data.
NextCure and LegoChem Biosciences have announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.
EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m ($2.37m) in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (‘DTIF’).
Gene therapy company Kriya Therapeutics is acquiring Redpin Therapeutics, a privately held biotech developing regulatable gene therapies for intractable diseases of the nervous system.
The US Food and Drug Administration (FDA) has approved Provention Bio’s Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes: with the American Diabetes Association welcoming it as a 'tremendous accomplishment'.
Roche announced yesterday that Phase 3 studies for its Alzheimer’s drug gantenerumab failed to meet the primary endpoint of slowing clinical decline. Although disappointed, Alzheimer’s associations are hopeful there is still a lot that can be learned...
Apollo Therapeutics and The Institute of Cancer Research in London have entered into a strategic collaboration to discover and develop new cancer medicines.
Cue Biopharma has released positive data at SITC 2022 from its ongoing Phase 1 trial evaluating its lead interleukin 2 (IL-2)-based biologic, CUE-101, in combination with KEYTRUDA, as a first line therapy for patients with recurrent/metastatic HPV+ head...
EdiGene Biotechnology USA has moved into a new Research & Development Center in Waltham, Mass. to advance its proprietary LEAPER tech into in vivo RNA editing therapies: with an initial focus on ophthalmology and the central nervous system.
Sanofi and Insilico Medicine have announced a multi-year, multi-target strategic research collaboration: leveraging Insilico’s ‘Pharma.AI’ platform to advance drug development for up to six new targets.
Chameleon Biosciences, a Berkeley-based biotech aiming to enable safer and more effective gene therapies, has won the Immunomodulatory Solution of the Year in the Biotech Breakthrough Awards, run by the Tech Breakthrough organization.
One dose of an antibody drug protected from malaria infection during the malaria season in Mali, showing up to 88% effectiveness: demonstrating for the first time that a monoclonal antibody can prevent malaria in an endemic region.
BioNTech is set to take several mRNA candidates into clinical trials over the coming months: including vaccines for shingles, malaria and tuberculosis.
Sensorion, a biotech specializing in therapies for hearing loss disorders, has been granted Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its lead gene therapy candidate, OTOF-GT.
Harro Höfliger and leon-nanodrugs GmbH (LEON) are teaming up on a manufacturing device to encapsulate mRNAs or active pharmaceutical ingredients (APIs) into lipid nanoparticles (LNPs).
IGM Biosciences is teaming up with ADC Therapeutics on a clinical trial collaboration and supply agreement to assess the combination of an IgM antibody and an ADC for the treatment of patients with relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma...
CSL Limited has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings to access its late stage, next-generation self-amplifying mRNA (sa-mRNA) vaccine tech: prepared to spend more than $4bn on the deal to accelerate its...
Lonza is to increase the size of the cell and gene therapy (CGT) development space at its Houston facility; the expansion will include viral vector-based process development and analytical development laboratories.
CPhI Frankfurt takes place next week: covering the full supply chain from research and manufacturing to packaging and finished products. Here’s five ideas on how to make the most of the event.
A ‘significant shift’ is under way in global outsourcing strategies: with the sector moving away from phase-appropriate development in favor of a more forward-looking model – with experts advising starting the search for an outsourcing partner as early...
Acumen Pharmaceuticals believes ACU193 – the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβO) – offers the promise of an effective treatment with a better safety profile than other Alzheimer's...
London investment fund Syncona will acquire retinal gene therapy company Applied Genetic Technologies Corporation (AGTC): with AGTC noting it had been facing ‘significant challenges’ in funding operations beyond 2022.
AbbVie will acquire DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins.
Cholera outbreak response campaigns should now use single-dose instead of two-dose vaccination campaigns, the WHO recommends, as it highlights global cholera vaccine shortages. It is calling on the world’s leading vaccine manufacturers to step up and...
Israel’s Sheba Medical Center, the largest hospital in the Middle East region, has initiated a collaborative project with Regeneron focused on oncology research and accelerating the development of potential novel therapeutics.
Yapan Bio, a contract development and manufacturing organization (CDMO) based in India, says it can now support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.
The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.
Cardiff-based CatSci is investing in its oligonucleotides capability that will enable the company to make oligos from nanomole quantities up to 30 grams using solid phase synthesis.
Eli Lilly and Company will acquire Akouos, a precision genetic medicine company developing a portfolio of adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
GSK’s respiratory syncytial virus (RSV) vaccine for adults aged 60+ has demonstrated overall vaccine efficacy of 82.6% against RSV lower respiratory tract disease (RSV-LRTD) - and a 94.1% reduction in severe RSV - in Phase 3 trials.
Merck has exercised its option to jointly develop and commercialize a personalized cancer vaccine (PVC) with Moderna following 'significant progress' made by the two companies in the field to date.
Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today. However, researchers say delivery of vaccines...
BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.
Lumen Bioscience says new data has been released demonstrating that its needle-free, spirulina-produced recombinant vaccinate protects against malaria.
Biogen has started a global Phase 2/3 study for litifilimab, a humanized IgG1 monoclonal antibody (mAb), in participants with cutaneous lupus erythematosus (CLE).
Kibow Biotech is celebrating its 25th anniversary as the company pivots toward developing a drug based on its proprietary probiotic strains that benefit kidney disease suffers.
Samsung Biologics has introduced two new platforms focused on optimized antibody production and systematic screening of molecules at an early development stage.
Vitamin D supplementation does not influence the efficacy or immunogenicity of SARS-CoV-2 vaccinations in patients with sub-optimal levels prior to vitamin treatment, according to a new study.
